SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Jin Yong Chung, Ji Won Lee, Choon Ho Ryu, Hye Kyung Min, Yeo Jin Yoon, Mi Jung Lim, Cheol Hyoung Park, 1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease, Journal of Neuroscience Research, 2015, 93, 5
  2. 2
    Salvatore Galati, Alessandro Stefani, Deep brain stimulation of the subthalamic nucleus: All that glitters isn't gold?, Movement Disorders, 2015, 30, 3
  3. 3
    Ashish Kumar Kakkar, Neha Dahiya, Management of Parkinson׳s disease: Current and future pharmacotherapy, European Journal of Pharmacology, 2015, 750, 74

    CrossRef

  4. 4
    Amaal Al Dakheel, Isabelle Beaulieu-Boire, Susan H Fox, Emerging drugs for levodopa-induced dyskinesia, Expert Opinion on Emerging Drugs, 2014, 19, 3, 415

    CrossRef

  5. 5
    F.I. Tarazi, Z.T. Sahli, M. Wolny, S.A. Mousa, Emerging therapies for Parkinson's disease: From bench to bedside, Pharmacology & Therapeutics, 2014, 144, 2, 123

    CrossRef

  6. 6
    Anne-Catherine Vijverman, Susan H Fox, New treatments for the motor symptoms of Parkinson’s disease, Expert Review of Clinical Pharmacology, 2014, 7, 6, 761

    CrossRef

  7. 7
    Eva Schaeffer, Andrea Pilotto, Daniela Berg, Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease, CNS Drugs, 2014, 28, 12, 1155

    CrossRef

  8. 8
    Rukmini Mridula Kandadai, Shaik Afshan Jabeen, Meena A Kanikannan, Rupam Borgohain, Safinamide for the treatment of Parkinson’s disease, Expert Review of Clinical Pharmacology, 2014, 7, 6, 747

    CrossRef

  9. You have free access to this content9
    Rupam Borgohain, Jozsef Szasz, Paolo Stanzione, Chandrashekhar Meshram, Mohit H. Bhatt, Dana Chirilineau, Fabrizio Stocchi, Valentina Lucini, Rodolfo Giuliani, Emma Forrest, Patricia Rice, Ravi Anand, Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease, Movement Disorders, 2014, 29, 10